Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358269 | 0.87 | NPC1 (0.30) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3354520 | 0.83 | CYP11B1 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL885250 | 0.75 | NPC1 (0.55) | CYP11B1CYP11B2NPC1MAPK13MAPK12 | |
| SCHEMBL986343 | 0.75 | NPC1 (0.55) | CYP11B1CYP11B2NPC1MAPK13MAPK12 | |
| SCHEMBL3353117 | 0.72 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL8556611 | 0.72 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3357269 | 0.71 | CRBN (0.39) | CYP11B1CYP11B2NPC1MAPK13MAPK12 | |
| SCHEMBL3622863 | 0.70 | MAOA (0.42) | — | |
| SCHEMBL2060589 | 0.70 | CA9 (0.44) | CYP11B1CYP11B2NPC1 | |
| SCHEMBL443143 | 0.69 | AHR (0.53) | CYP11B1CYP11B2NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CYP11B1 1005/4885CYP11B2 894/4885NPC1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.